The 20 Best Renal Cell Carcinoma (RCC) Doctors Near Me in Michigan, US

Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Orchiectomy.

Ajjai Alva is an Oncologist in Ann Arbor, Michigan. Dr. Alva is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Urothelial Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Simpa S. Salami, M.D., M.P.H. is a fellowship-trained, board-certified Urologic Oncologist and Associate Professor of Urology at the University of Michigan. He obtained his medical degree from the College of Medicine, University of Ibadan, Nigeria. Thereafter, he completed a Master of Public Health program at Harvard University, General Surgery Internship at the Brigham and Women’s Hospital in Boston, Urology Residency at Hofstra Northwell Health School of Medicine in New York, and Urologic Oncology Fellowship at the University of Michigan in Ann Arbor, Michigan. Dr. Salami’s clinical expertise is in the minimally invasive surgical treatment of prostate and kidney cancer. As a translational surgeon-scientist, his laboratory focuses on developing novel cancer biomarkers to overcome tumor heterogeneity and multifocality as well as elucidate optimal paradigms for early detection of urologic cancers, risk stratification, prognostication, and prediction of treatment response. Dr. Salami’s lab collaborates with investigators all over the world to understand the molecular underpinnings of urologic cancer and associated disparities. Dr. Salami is a recipient of several awards including the: Harvard University Presidential Scholar, Prostate Cancer Foundation Young Investigator, American Urological Association (AUA) Urology Care Foundation (UCF) Research Scholar, AUA UCF Rising Stars in Urologic Research, Harold Amos Medical Faculty Development Fellowship, Rogel Cancer Center Scholar, Society of Urologic Oncology Young Investigator, NCI R37 MERIT and 2024 AUA Gold Cystoscope Awards. Most recently, he was named an inaugural Biden White House Cancer Moonshot Scholar. He has served on several National guideline committees, such as the AUA Prostate Cancer Early Detection Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, and the Society of Nuclear Medicine and Imaging PSMA PET Appropriate Use Criteria Working Group. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and the Prostate Cancer Foundation. Dr. Salami is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Prostatectomy.

Samuel Kaffenberger is a Urologist in Brighton, Michigan. Dr. Kaffenberger has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Urothelial Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Khaled Hafez is a Urologist in Ann Arbor, Michigan. Dr. Hafez is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Nephrectomy, and Cystectomy.

Wassim Bazzi is a Urologist in Dearborn, Michigan. Dr. Bazzi has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Obstructive Uropathy, Hydronephrosis, Nephrectomy, and Ureteroscopy. Dr. Bazzi is currently accepting new patients.

Brian Seifman is a Urologist in Rochester Hills, Michigan. Dr. Seifman has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Kidney Stones, Congenital Mesoblastic Nephroma, Enlarged Prostate (BPH), Ureteroscopy, and Lithotripsy. Dr. Seifman is currently accepting new patients.

Jason Hafron is a Urologist in Troy, Michigan. Dr. Hafron has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Enlarged Prostate (BPH), Familial Prostate Cancer, Prostatectomy, and Aquablation. Dr. Hafron is currently accepting new patients.

Conrad Tobert is an Oncologist and a Urologist in Grand Rapids, Michigan. Dr. Tobert has been practicing medicine for over 12 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Prostate Cancer, Nephrectomy, and Ureteroscopy. Dr. Tobert is currently accepting new patients.

Kenneth Kernen is a Urologist in Troy, Michigan. Dr. Kernen has been practicing medicine for over 33 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Enlarged Prostate (BPH), Perirenal Abscess, Nephrectomy, and Reconstructive Urology Surgery. Dr. Kernen is currently accepting new patients.

Daniel Barkmeier is a Radiologist in Ann Arbor, Michigan. Dr. Barkmeier is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Thyroid Nodule, Adrenal Cancer, and Renal Cell Carcinoma (RCC).

John Anema is a Urologist in Grand Rapids, Michigan. Dr. Anema has been practicing medicine for over 38 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Reconstructive Urology Surgery. Dr. Anema is currently accepting new patients.

Shane Wells is a Radiologist in Ann Arbor, Michigan. Dr. Wells is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Ascites, Visceromegaly, Cardiac Ablation, and Nephrectomy.

Christopher Brede is an Oncologist and a Urologist in Grand Rapids, Michigan. Dr. Brede has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Reconstructive Urology Surgery. Dr. Brede is currently accepting new patients.

Ryan Nelson is a Urologist in Utica, Michigan. Dr. Nelson has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Bilateral Hydronephrosis, Hydronephrosis, Obstructive Uropathy, Nephrectomy, and Ureteroscopy. Dr. Nelson is currently accepting new patients.

Peter Winston is a Radiologist in Saint Clair Shores, Michigan. Dr. Winston is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Carbuncle, Folliculitis, Boils, and WT1-Related Wilms Tumor Syndromes.

Dr. Davenport is an internationally recognized expert on the safety and efficacy of radiographic contrast material. He has served on the U.S. Food and Drug Administration Medical Imaging Drugs Advisory Committee, the National Cancer Institute Clinical Imaging Steering Committee, and the American College of Radiology's Committee on Drugs on Contrast Media (current chair). He has numerous national responsibilities, is a co-author on national policy statements, has published over 150 manuscripts, was founder of the Michigan Radiology Quality Collaborative, and is a funded investigator. His primary clinical interests include patient safety, high-value care, and urologic imaging. Dr. Davenport is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, WT1-Related Wilms Tumor Syndromes, Prostatectomy, and Cardiac Ablation.

Gregory Oldford is a Urologist in Brighton, Michigan. Dr. Oldford is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Enlarged Prostate (BPH), Prostate Cancer, Familial Prostate Cancer, UPJ Obstruction, and Ureteroscopy.

Ganesh S. Palapattu, MD, FACS is The George F. and Sandy G. Valassis Professor and Chair of the Department of Urology. He joined the University of Michigan Department of Urology as Associate Professor and Chief of Urologic Oncology in the Fall of 2012. Prior to this he was the Chief of Urologic Oncology at Houston Methodist Hospital in Houston, Texas. Dr. Palapattu has held faculty appointments at the University of Rochester School of Medicine in Rochester, NY where he was also Assistant Residency Program Director and Weill Cornell Medical College/The Houston Methodist Hospital.Dr. Palapattu was born in Toronto, Canada where he developed a passion for street hockey. At the age of 9, his family moved to Houston, Texas where he picked up playing the French horn. Dr. Palapattu graduated from the University of Texas at Austin with a B.A. degree in the Humanities and subsequently attended Baylor College of Medicine. Dr. Palapattu received his surgical/urological training at the David Geffen School of Medicine at UCLA and further specialty training in urologic oncology at Johns Hopkins. He and his wife, Anu, whom he met at UT Austin, have 2 young children. The Palapattu family is enthusiastic about taking advantage of the many outdoor activities the Ann Arbor area affords.When not working, Dr. Palapattu enjoys spending time with his family, traveling and playing/watching sports. Go Blue!. Dr. Palapattu is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Prostatectomy.

Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies. Dr. Morgan is originally from Seattle, WA, and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. Dr. Morgan is a translational surgeon-scientist, and his research spans the spectrum from preclinical laboratory-based research to prospective clinical trials. The primary focus of his laboratory is on identifying key pathways that predict response and resistance to treatment in genitourinary malignancies. This includes work in prostate cancer to develop liquid biopsy approaches that can guide precision-based therapeutic strategies in real time, as well as ongoing research in renal cell carcinoma to identify genomic signatures for risk stratification.Dr. Morgan is currently an Associate Professor of Urology and has been at the University of Michigan since 2012. In addition to his research pursuits, he is a busy clinician and surgeon offering advanced robotic, laparoscopic, and open surgical approaches for patients with genitourinary malignancies. He has substantial expertise in the use and interpretation of molecular biomarkers, which can help guide individualized treatment choice for some patients.Beyond work, he loves his time enjoying the great town of Ann Arbor and beautiful state of Michigan with his wife, Wendy, and their two young boys. Whether camping in Petoskey, sitting on a beach in Grand Haven, or biking around the neighborhood in Ann Arbor, the Morgan family has quickly learned that life in the Midwest is hard to beat. Dr. Morgan is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Prostatectomy, and Nephrectomy.